The Patent Finder

Aduro Gvax Inc.

Also on record
Records under this name other than patents Aduro Gvax Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Aduro Gvax Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,919,079Cancer Immunotherapy Compositions and Methods of Use
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,580,247PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 7,901,902Methods and Compositions for Identifying a Cellular Immune Response Against Prostate Cancer
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,669,081Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,840,881Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer
Formerly held
Lapsed on the fee record
Ended Sep 23, 2026 · High confidence
Lapsed on the fee recordEnded Sep 23, 2026High confidence
US 7,176,022Directly injectable formulations which provide enhanced cryoprotection of cell products
Formerly held
Term ended
Term ended Feb 27, 2024 · USPTO record
Term endedTerm ended Feb 27, 2024USPTO record
US 9,848,598Cryoprotected, frozen recombinant cancer cells
Formerly held
Term ended
Ended no later than Dec 20, 2022 · USPTO record
Term endedEnded no later than Dec 20, 2022USPTO record
US 8,287,856PD-1 Antibodies in Combination with a Cytokine-Secreting Cell and Methods of Use Thereof
Lapsed on the fee record
Ended Oct 16, 2020 · Medium confidence
Lapsed on the fee recordEnded Oct 16, 2020Medium confidence
US 9,433,204Directly injectable formulations which provide enhanced cryoprotection of cell products
Lapsed on the fee record
Ended Sep 6, 2020 · USPTO record
Lapsed on the fee recordEnded Sep 6, 2020USPTO record
US 7,645,587Novel Cancer-Associated Antigens and Methods of Their Identification and Use
Term ended
Term ended Nov 3, 2019 · Medium confidence
Term endedTerm ended Nov 3, 2019Medium confidence
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited